Makes sense, nidan . The good thing is that it will require much fewer test subjects and will be short in duration. We all should know by the end of 2017 how it worked. It definitely would validate the sigma-1 receptor agonist approach and the homeostasis that is thereby restored. Any CNS disorder that can benefit from that mode of treatment will be advantageous to both the patients and certainly to the shareholders. It's going to be fun to be a part of it.
I agree 100%...short trial and if Retts is successful it will give Anavex success to build off and bring credibility to Missling, the BOD and Anavexs drugs and the Sigma One Platform they are touting. If we get FDA approval for Retts, we are a $30-40 stock all day long, and maybe higher. If it works on Retts, it probably works on everything else.
News 
Market Data 
Discover 
